Robert J. Wechsler-Reya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert J. Wechsler-Reya has a total of 721 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Taylor
Texas Children’s Hospital, Baylor College of Medicine , Houston, Texas
47 shared publications - Marc Remke
Department of Pediatric Oncology and Hematology, Saarland University, Medical Center, Homburg, Germany
39 shared publications - Alexandra Garancher
Tumor Initi-ation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, California
38 shared publications - Jessica M. Rusert
Tumor Initi-ation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, California
38 shared publications - Sara Bolin
Department of Immunology, Genetics, and Pathology, Science for Life Labora-tory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
38 shared publications - Ulrich Schüller
Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany
38 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-10
Medulloblastoma on the Move: How Tumor Cells Colonize the Leptomeninges – and How to Stop Them
- 31 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-10
Open AccessMedulloblastoma on the Move: How Tumor Cells Colonize the Leptomeninges – and How to Stop Them
- Open Access
- 14 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (38)
Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing
Medulloblastomas are considered immunologically cold and refractory to immunotherapy. One factor contributing to their low immunogenicity is impaired antigen presentation, which allows tumor cells to evade cytotoxic T cells. Using a syngeneic mouse model of medulloblastoma, we demonstrate that despite low expression of MHC class I on tumor cells, depletion of CD8 + T cells accelerates tumor growth, whereas adoptive transfer of tumor-reactive CD8 + T cells prolongs survival. These antitumor effects rely on T cell–derived interferon gamma (IFNγ), which induces MHC class I on tumor cells and facilitates tumor cell killing by T cells. Importantly, delivering IFNγ directly into tumors via convection-enhanced delivery enhances CD8 + T cell–mediated killing of tumor cells and significantly prolongs survival in tumor-bearing mice. These studies highlight the importance of T cells in controlling brain tumors and the value of IFNγ as an adjuvant for T cell–based immunotherapy.
- 14 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (38)
Open AccessLocal delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing
Medulloblastomas are considered immunologically cold and refractory to immunotherapy. One factor contributing to their low immunogenicity is impaired antigen presentation, which allows tumor cells to evade cytotoxic T cells. Using a syngeneic mouse model of medulloblastoma, we demonstrate that despite low expression of MHC class I on tumor cells, depletion of CD8 + T cells accelerates tumor growth, whereas adoptive transfer of tumor-reactive CD8 + T cells prolongs survival. These antitumor effects rely on T cell–derived interferon gamma (IFNγ), which induces MHC class I on tumor cells and facilitates tumor cell killing by T cells. Importantly, delivering IFNγ directly into tumors via convection-enhanced delivery enhances CD8 + T cell–mediated killing of tumor cells and significantly prolongs survival in tumor-bearing mice. These studies highlight the importance of T cells in controlling brain tumors and the value of IFNγ as an adjuvant for T cell–based immunotherapy.
- Open Access
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
CD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessCD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- Open Access
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1753-1768
ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma
Medulloblastoma is the most common malignant pediatric brain tumor, and has an urgent need for novel treatment approaches. Dordaviprone (ONC201) and its chemical derivative with nanomolar potency, ONC206, induce apoptosis of cancer cells by activation of the mitochondrial caseinolytic protease P (ClpP). ONC206 is currently in Phase I clinical trials for pediatric patients with primary brain tumors. In this study, we evaluated the preclinical therapeutic effects of ONC206 in medulloblastoma and investigated its mechanism of action. We found evidence for high expression of ClpP at both the RNA and protein level in medulloblastoma tumors, compared to very low expression in normal brain tissue. In addition, we saw a pronounced reduction in cell viability of human Group 3 and Group 4 and murine SHH-driven and Group 3 medulloblastoma cells treated with ONC206 with low IC-50s. After treatment with ONC206, we observed an induction of integrated stress response and mitochondrial damage. To test the efficacy of ONC206 in vivo, we used murine models of SHH-driven and Group 3 medulloblastoma as well as Group 3 and Group 4 patient-derived xenografts (PDXs). ONC206 led to a significant prolongation of survival in both murine models, with the SHH mice demonstrating survival extension from 70 to 140 days. PDX-bearing mice also responded to ONC206, which led to a significant survival benefit. Our results highlight ONC206 as a novel therapeutic option for patients with high-risk medulloblastoma and provide strong rationale for testing the efficacy of ONC206 in the treatment of these patients.
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1753-1768
Open AccessONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma
Medulloblastoma is the most common malignant pediatric brain tumor, and has an urgent need for novel treatment approaches. Dordaviprone (ONC201) and its chemical derivative with nanomolar potency, ONC206, induce apoptosis of cancer cells by activation of the mitochondrial caseinolytic protease P (ClpP). ONC206 is currently in Phase I clinical trials for pediatric patients with primary brain tumors. In this study, we evaluated the preclinical therapeutic effects of ONC206 in medulloblastoma and investigated its mechanism of action. We found evidence for high expression of ClpP at both the RNA and protein level in medulloblastoma tumors, compared to very low expression in normal brain tissue. In addition, we saw a pronounced reduction in cell viability of human Group 3 and Group 4 and murine SHH-driven and Group 3 medulloblastoma cells treated with ONC206 with low IC-50s. After treatment with ONC206, we observed an induction of integrated stress response and mitochondrial damage. To test the efficacy of ONC206 in vivo, we used murine models of SHH-driven and Group 3 medulloblastoma as well as Group 3 and Group 4 patient-derived xenografts (PDXs). ONC206 led to a significant prolongation of survival in both murine models, with the SHH mice demonstrating survival extension from 70 to 140 days. PDX-bearing mice also responded to ONC206, which led to a significant survival benefit. Our results highlight ONC206 as a novel therapeutic option for patients with high-risk medulloblastoma and provide strong rationale for testing the efficacy of ONC206 in the treatment of these patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.